Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Hematologic Neoplasms × acalabrutinib × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 9 Lymphoma, Mantle-Cell 5 Lymphoma, Non-Hodgkin 4 Lymphoma 3 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, Follicular 2 Leukemia 2 Waldenstrom Macroglobulinemia 1 Multiple Myeloma 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Leukemia, Prolymphocytic 1 Leukemia, Hairy Cell 1 Leukemia, B-Cell 1 Hodgkin Disease 1 Hematologic Neoplasms 1 Glioblastoma 1 DLBCL 1 Burkitt Lymphoma 1

Interventions

fludarabine 17 Cyclophosphamide 17 Whole-Body Irradiation 9 Tacrolimus 9 venetoclax 7 fludarabine phosphate 7 Sirolimus 7 Mycophenolic Acid 7 Azacitidine 6 Mesna 5 Bortezomib 5 Rituximab 4 Methotrexate 4 Dexamethasone 4 Busulfan 4 daratumumab 3 Stem Cell Transplantation 3 Peripheral Blood Stem Cell Transplantation 3 Melphalan 3 Lenalidomide 3 Filgrastim 3 Biopsy 3 Alemtuzumab 3 pomalidomide 2 merphos 2 ibrutinib 2 Thiotepa 2 Radiotherapy 2 Prednisone 2 Hematopoietic Stem Cell Transplantation 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05205252 2023-08-15

ARIA

Ipsen

Phase 1/2 Withdrawn

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡